Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 10 of 10

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2017

Evaluation of time-to-recurrence of disease activity in treatment-naïve patients with neovascular age-related macular degeneration after ranibizumab treatment: 12-month analysis from the ORACLE study

Maddalena Quaranta; François DEVIN; Gabriel QUENTEL; Joël UZZAN; Eric Fourmaux; Laurent CASTELNOVO; Wilfried ROQUET; Catherine FRANCAIS-MAURY; Sam RAZAVI; Nathalie San Nicolas

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):900.

ARVO Annual Meeting Abstract June 2017

Real-world outcomes with ranibizumab 0.5 mg in treatment-naïve French patients with visual impairment due to diabetic macular edema: 12-month results from the ETOILE study

Eric Fourmaux; Amélie LECLEIRE-COLLET; Corinne DOT; Marie-Laure LE LEZ; Stéphanie BAILLIF; Ali Erginay; Eric Souied; Philippe GAIN; Laurent KODJIKIAN; Laetitia FINZI

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4625.

ARVO Annual Meeting Abstract September 2016

Time to recurrence in neovascular age-related macular degeneration after ranibizumab treatment: baseline characteristics of treatment-naive patients enrolled in the ORACLE study

François Devin; Eric Fourmaux; gabriel quentel; Joel Uzzan; Maddalena QUARANTA EL-MAFTOUHI; Catherine Français-Maury; Wilfried Roquet; Laurent Castelnovo; Sam Razavi; Laetitia Finzi

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3353.

ARVO Annual Meeting Abstract April 2014

RAVE2 Study : Two years treatment follow up with intravitreal ranibizumab (Lucentis®) and verteporfin PDTRF combination therapy at month 2 for neovascular age-related macular degeneration (AMD)

Marcel Dominguez; Eric Fourmaux; Laurence Rosier; Laurent Velasque

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):3961.

ARVO Annual Meeting Abstract March 2012

One year’s treatment with intravitreal Ranibizumab (lucentis®) and Verteporfin PDTRf Combination Therapy at Month 2 for Neovascular Age-related Macular Degeneration (AMD)

Eric Fourmaux; marcel dominguez; laurence rosier; laurent velasque

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):6525.

ARVO Annual Meeting Abstract May 2006

Posterior Sub–Tenon’s Injection of Triamcinolone Acetonide in Exudative AMD: Effects on Macular Thickness

M.–N. Delyfer; M.–B. Rougier; E. Fourmaux; J.–F. Korobelnik

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):5248.

ARVO Annual Meeting Abstract May 2005

Sub–Tenon’s Triamcinolone Combined With Photodynamic Therapy for Subfoveal Choroidal Neovascularisation in Age–related Macular Degeneration

M.B. Rougier; E. Fourmaux; A. Dufoix; M.N. Delyfer; J.F. Korobelnik

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):319.

ARVO Annual Meeting Abstract May 2003

Transpupillary Thermotherapy of Occult Choroidal Neovascularization: One-Year Results

M.B. Rougier; L. François; E. Fourmaux; R. Isber; J. Colin; J.F. Korobelnik

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):1813.

ARVO Annual Meeting Abstract December 2002

Transpupillary Treatment of Occult Choroidal Neovascularization : preliminary results

MB Rougier; R Isber; M Alami; E Fourmaux; JF Korobelnik

Invest. Ophthalmol. Vis. Sci.. 2002; 43(13):4420.

ARVO Annual Meeting Abstract December 2002

Photodynamic Therapy for Choroidal Neovascularization in Age Related Macular Degeneration and Pathologic Myopia: Lens Status Implication

R Isber-Soyeur; M-B Rougier; T Darquies; H Manic; H Manic; E Fourmaux; N Chobaux; J-F Korobelnik

Invest. Ophthalmol. Vis. Sci.. 2002; 43(13):605.

Advertisement